279 related articles for article (PubMed ID: 23564564)
1. Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma.
Lee D; Chung YH; Kim JA; Park WH; Jin YJ; Shim JH; Ryu SH; Jang MK; Yu E; Lee YJ
Cancer; 2013 Jun; 119(12):2239-46. PubMed ID: 23564564
[TBL] [Abstract][Full Text] [Related]
2. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.
Tanimoto Y; Tashiro H; Aikata H; Amano H; Oshita A; Kobayashi T; Kuroda S; Tazawa H; Takahashi S; Itamoto T; Chayama K; Ohdan H
Ann Surg Oncol; 2012 Feb; 19(2):418-25. PubMed ID: 21710324
[TBL] [Abstract][Full Text] [Related]
3. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.
Hagihara H; Nouso K; Kobayashi Y; Iwasaki Y; Nakamura S; Kuwaki K; Toshimori J; Miyatake H; Ohnishi H; Shiraha H; Yamamoto K
Int J Clin Oncol; 2011 Jun; 16(3):210-20. PubMed ID: 21152943
[TBL] [Abstract][Full Text] [Related]
4. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
[TBL] [Abstract][Full Text] [Related]
5. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.
Chen LT; Chen MF; Li LA; Lee PH; Jeng LB; Lin DY; Wu CC; Mok KT; Chen CL; Lee WC; Chau GY; Chen YS; Lui WY; Hsiao CF; Whang-Peng J; Chen PJ;
Ann Surg; 2012 Jan; 255(1):8-17. PubMed ID: 22104564
[TBL] [Abstract][Full Text] [Related]
7. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
Hsu YC; Ho HJ; Wu MS; Lin JT; Wu CY
Hepatology; 2013 Jul; 58(1):150-7. PubMed ID: 23389758
[TBL] [Abstract][Full Text] [Related]
8. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma.
Ryu SH; Chung YH; Lee H; Kim JA; Shin HD; Min HJ; Seo DD; Jang MK; Yu E; Kim KW
Hepatology; 2008 Mar; 47(3):929-36. PubMed ID: 18306220
[TBL] [Abstract][Full Text] [Related]
9. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
10. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis.
Xu J; Li J; Chen J; Liu ZJ
Adv Clin Exp Med; 2015; 24(2):331-40. PubMed ID: 25931368
[TBL] [Abstract][Full Text] [Related]
11. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
[TBL] [Abstract][Full Text] [Related]
13. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
[TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.
Lo CM; Liu CL; Chan SC; Lam CM; Poon RT; Ng IO; Fan ST; Wong J
Ann Surg; 2007 Jun; 245(6):831-42. PubMed ID: 17522506
[TBL] [Abstract][Full Text] [Related]
15. Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.
Qi W; Zhang Q; Xu Y; Wang X; Yu F; Zhang Y; Zhao P; Guo H; Zhou C; Wang Z; Sun Y; Liu L; Xuan W; Wang J
J Viral Hepat; 2020 Apr; 27(4):387-396. PubMed ID: 31755220
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Kudo M
Oncology; 2011; 81 Suppl 1():50-5. PubMed ID: 22212936
[TBL] [Abstract][Full Text] [Related]
17. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
Yu ML; Lee CM; Chen CL; Chuang WL; Lu SN; Liu CH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Su WW; Lin CL; Yang HC; Chen PJ; Chen DS; Liu CJ;
Hepatology; 2013 Jun; 57(6):2135-42. PubMed ID: 23322699
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma.
Qu LS; Jin F; Huang XW; Shen XZ
J Surg Oncol; 2010 Dec; 102(7):796-801. PubMed ID: 20886584
[TBL] [Abstract][Full Text] [Related]
19. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant pegylated interferon therapy improves the survival outcomes in patients with hepatitis-related hepatocellular carcinoma after curative treatment: A meta-analysis.
Wu J; Yin Z; Cao L; Xu X; Yan T; Liu C; Li D
Medicine (Baltimore); 2018 Jul; 97(28):e11295. PubMed ID: 29995763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
